Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis

Associations Between Canada's Cannabis Legalization and Emergency Department Presentations for Transient Cannabis-Induced Psychosis and Schizophrenia Conditions: Ontario and Alberta, 2015–2019

(2022) Russell C. Callaghan et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial

(2022) Itxaso González-Ortega et al.   International Journal of Environmental Research and Public Health

Surface-based brain morphometry in schizophrenia vs. cannabis-induced psychosis: A controlled comparison

(2022) Abhishek Ghosh et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

(2022) Valerio Ricci et al.   International Journal of Environmental Research and Public Health

Do neurocognitive functions in cannabis induced psychosis groups differ from schizophrenia with cannabis use? A controlled cross-sectional study

(2021) Raghav Shah et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Improving Patient Flow and Access to Care at an Academically Affiliated Urban Safety-Net Hospital

(2021) Melanie Rylander et al.   PSYCHIATRIC SERVICES

Substance-Induced Psychoses: An Updated Literature Review

(2021) Alessio Fiorentini et al.   Frontiers in Psychiatry

Psicosis inducida por cannabis: características clínicas y su diferenciación con la esquizofrenia con y sin consumo de cannabis asociado

(2020) David Rentero Martín et al.   Adicciones

Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial

(2019) Luke Sheridan Rains et al.   BMC Medicine

Impact of first episode psychosis treatment on heavy cannabis use: Secondary analysis on RAISE-ETP study

(2019) Karl C. Alcover et al.   SCHIZOPHRENIA RESEARCH

Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016

(2019) Carsten Hjorthøj et al.   PSYCHOLOGICAL MEDICINE

Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis

(2018) Marie Stefanie Kejser Starzer et al.   AMERICAN JOURNAL OF PSYCHIATRY

Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial

(2018) Corinne Cather et al.   PSYCHIATRY RESEARCH

International trends in antipsychotic use: A study in 16 countries, 2005–2014

(2017) Óskar Hálfdánarson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects

(2017) Spyridon Siafis et al.   Current Neuropharmacology

Antipsychotic Medication Prescribing in Children Enrolled in Medicaid

(2015) D. C. Rettew et al.   PEDIATRICS

Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up

(2015) M. Smeerdijk et al.   PSYCHOLOGICAL MEDICINE

SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process: Table 1

(2015) Greg Ogrinc et al.   BMJ Quality & Safety

A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial

(2014) C. Barrowclough et al.   PSYCHOLOGICAL MEDICINE

Aripiprazole for Treating Cannabis-Induced Psychotic Symptoms in Ultrahigh-Risk Individuals

(2013) Benjamin Rolland et al.   CLINICAL NEUROPHARMACOLOGY

Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial

(2012) C. R. Hjorthøj et al.   PSYCHOLOGICAL MEDICINE

A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness

(2012) Kevin Madigan et al.   SCHIZOPHRENIA RESEARCH

Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes

(2011) Serge Sevy et al.   PSYCHIATRY RESEARCH

Motivational Intervention to Reduce Cannabis Use in Young People with Psychosis: A Randomized Controlled Trial

(2011) Charles Bonsack et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans

(2010) Joshua A Lile et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effect of Early Dysphoric Response and Cannabis Use on Discontinuation of Olanzapine or Risperidone in Patients With Early Psychosis

(2010) L. van Nimwegen-Campailla et al.   PHARMACOPSYCHIATRY

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence

(2009) Raymond F. Anton et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice

(2008) Elisabet Jerlhag   ALCOHOL

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice

(2007) Juliana V. Leite et al.   EUROPEAN JOURNAL OF PHARMACOLOGY